Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

• Main Authors: Yvo J.M. op den Kamp (Author), Anne Gemmink (Author), Marlies de Ligt (Author), Bas Dautzenberg (Author), Esther Kornips (Author), Johanna A. Jorgensen (Author), Gert Schaart (Author), Russell Esterline (Author), Diego A. Pava (Author), Joris Hoeks (Author), Vera B. Schrauwen-Hinderling (Author), Sander Kersten (Author), Bas Havekes (Author), Timothy R. Koves (Author), Deborah M. Muoio (Author), Matthijs K.C. Hesselink (Author), Jan Oscarsson (Author), Esther Phielix (Author), Patrick Schrauwen (Author)
• Format: Book
• Published: Elsevier, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes; the underlying mechanism may be metabolic adaptations due to urinary glucose loss. Here, we investigated the cellular and molecular effects of 5 weeks of dapagliflozin tre...